These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26602815)

  • 1. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.
    Pfister SX; Markkanen E; Jiang Y; Sarkar S; Woodcock M; Orlando G; Mavrommati I; Pai CC; Zalmas LP; Drobnitzky N; Dianov GL; Verrill C; Macaulay VM; Ying S; La Thangue NB; D'Angiolella V; Ryan AJ; Humphrey TC
    Cancer Cell; 2015 Nov; 28(5):557-568. PubMed ID: 26602815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
    Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
    Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
    Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An essential role for dNTP homeostasis following CDK-induced replication stress.
    Pai CC; Hsu KF; Durley SC; Keszthelyi A; Kearsey SE; Rallis C; Folkes LK; Deegan R; Wilkins SE; Pfister SX; De León N; Schofield CJ; Bähler J; Carr AM; Humphrey TC
    J Cell Sci; 2019 Mar; 132(6):. PubMed ID: 30674555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
    Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
    Murrow LM; Garimella SV; Jones TL; Caplen NJ; Lipkowitz S
    Breast Cancer Res Treat; 2010 Jul; 122(2):347-57. PubMed ID: 19821025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.